×
0 0 0.00269541778975747 0.00269541778975747 0.0107816711590297 0.0242587601078168 0.0134770889487871 -0.0107816711590295
Stockreport

CTI's European marketing application for pacritinib in certain myelofibrosis patients accepted for review; shares ahead 10% premarket [Seeking Alpha]

CTI BIOPHARMA CORP COMMON STOCK (CTIC)  More Company Research Source: Seeking Alpha
Last cti biopharma corp common stock earnings: 8/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ctibiopharma.com
PDF Thinly traded nano cap CTI BioPharma (NASDAQ: CTIC ) perks up   premarket on increased volume in response to its announcement that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) seeking approval of pacritinib for the treatment of myelofibrosis patients who have thrombocytopenia (low blood platelets). The review clock by the EMA's Committee for Medicinal Products for Human Use (CHMP) is 210 days, excluding question or opinion response periods. Pacritinib is an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. The JAK family of enzymes plays a key role in normal blood cell growth and development, immune responses and the expression of proinflammatory cytokines. Now read: Mylan breast cancer generic approved by FDA panel » [Read more]

IMPACT SNAPSHOT EVENT TIME: CTIC
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
CTIC alerts
from News Quantified
Opt-in for
CTIC alerts

from News Quantified
Opt-in for
CTIC alerts

from News Quantified